<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: <z:chebi fb="0" ids="31941">Oxaliplatin</z:chebi>-induced <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> is a dose-related side effect which occurs in almost 40 % of patients treated with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Aim of the present study was to identify reliable clinical factors predicting its development and duration </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: One hundred sixty-nine completely resected <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients treated with adjuvant Folfox IV regimen were retrospectively included </plain></SENT>
<SENT sid="3" pm="."><plain>The following pre-treatment clinical parameters were collected: <z:hpo ids='HP_0002901'>hypocalcaemia</z:hpo>, hypomagnesaemia, <z:hpo ids='HP_0003073'>hypoalbuminaemia</z:hpo>, <z:hpo ids='HP_0001903'>anaemia</z:hpo>, <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:hpo ids='HP_0003774'>chronic renal failure</z:hpo> (CRF), <z:chebi fb="3" ids="37445">folate</z:chebi> deficiency, <z:hpo ids='HP_0100502'>vitamin B12 deficiency</z:hpo>, number of cycles received and habit to alcohol consumption </plain></SENT>
<SENT sid="4" pm="."><plain>Incidence, grade (NCI-CTCAE v.3) and duration of <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> were recorded </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Incidence of <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> was found to be higher in patients with pre-treatment <z:hpo ids='HP_0001903'>anaemia</z:hpo> (p = 0.001), <z:hpo ids='HP_0003073'>hypoalbuminaemia</z:hpo> (p = 0.01) and hypomagnesaemia (p = 0.001) as well in those with habit to alcohol consumption (p = 0.003) </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">Neuropathy</z:e> durations were conversely associated with age, being longer in younger patients (p = 0.03), and again with <z:hpo ids='HP_0003073'>hypoalbuminaemia</z:hpo> (p = 0.04) and hypomagnesaemia (p = 0.002) </plain></SENT>
<SENT sid="7" pm="."><plain>No correlation was found with gender, <z:hpo ids='HP_0002901'>hypocalcaemia</z:hpo>, <z:mp ids='MP_0002055'>diabetes</z:mp> and CRF </plain></SENT>
<SENT sid="8" pm="."><plain>The correlation between <z:chebi fb="9" ids="17439">vitamin B12</z:chebi> and <z:chebi fb="3" ids="37445">folate</z:chebi> levels and the development of neurotoxicity were not analysed because of the high number of missing data in the population </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Age, <z:hpo ids='HP_0001903'>anaemia</z:hpo>, <z:hpo ids='HP_0003073'>hypoalbuminaemia</z:hpo>, hypomagnesaemia and alcohol consumption are reliable and easily assessable clinical factors predicting incidence and length of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-induced <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> </plain></SENT>
</text></document>